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S_ay The presence of specific and high affinity epidermal growth factor receptors (EGF-R) has been
demonstrated in human prostate cancer (CaP). Scatchard analysis of the binding data revealed a linear plot
consistent with a single class of binding sites with a mean dissociation constant (Kd) ± s.d. = 1.6+0.4nmol 1
Additionally the binding was specific for EGF since no other competitor than EGF was able to displace the
binding of the labelled ligand from its receptor. Comparison of the concentrations of EGF-R in tissues from
19 patients with CaP with those measured in a group of 18 patients with benign prostatic hyperplasia (BPH)
reveal that the expression of EGF-R was significantly higher in BPH (mean +s.d. = 125 +7fmolmg protein-1)
than in CaP (52+llfmolmg protein-'; P<0.01). Furthermore, in CaP the expression of EGF-R varied
according to the histological grade of the cancer: well differentiated tumours demonstrated more receptors
(84_ 13 fmol mgprotein-1) than poorly differentiated tumours (22_5fmolmg protein '; P<0.01). Clearly the
depletion in the expression of EGF receptors in CaP is a function of the histological grade of the cancer and
as such EGF receptors could be used as a biochemical marker for tumour differentiation.
The high incidence of prostatic cancer (CaP) has led to
intensified study of this gland during the past two decades.
The nature of the molecular changes responsible for the
disease has attracted the attention of many biochemists and
molecular biologists, but the complete solution to the cancer
problem still eludes the best efforts of both scientists and
clinicians. Early diagnosis and treatment are crucial. In this
connection a considerable amount of work on a variety of
substances synthesised and secreted by the prostate has been
carried out in order to gain insight into the pathogenesis of
this condition (Choe & Rose, 1982; Pontes et al., 1982).
Recently interest has focused on the many peptide growth
factors because of their regulatory action on tissue growth
(Sporn & Roberts, 1988).
Of particular interest is the epidermal growth factor
(EGF) polypeptide (molecular weight 6,045 daltons) which
stimulates proliferation and differentiation of a great vanrety
of cell types (Carpenter & Cohen, 1979). The activities of
EGF are mediated through its specific receptor, which is a
170 kilodalton glycoprotein located on the cell surface
membrane. Several reports showed that the binding activity
of EGF to the receptor in cancerous tissues was either
decreased (De Larco & Todaro, 1978) or increased
(Libermann et al., 1985; Cowley et al., 1986). Furthermore,
the receptor expression has been correlated with the metasta-
tic potential of the cancer (Gusterson et al., 1984; Sainsbury
et al., 1985; Neal et al., 1985; Cowley et al., 1986; Gullick
et al., 1986). Recent evidence indicates that the oncogene
v-erbB encodes a truncated EGF receptor which activates
the tyrosine kinase to a 'turned on' state, thereby obviating
the need for EGF stimulation (Downward et al., 1984). The
receptor was therefore thought to have some role in the
biological behaviour of carcinoma cells. Although the local-
isation of EGF receptors (EGF-R) in human benign prosta-
tic hyperplasia (BPH) has been established (Maddy et al.,
1987) and the importance of EGF in maintaining prostate
cell proliferation has been demonstrated (Chaproniere &
McKeehan, 1986) no reports have so far been published
concerning the presence of EGF-R in human prostate
cancer. In the present study we report for the first time the
biochemical localisation of EGF-R in CaP and compare it
with BPH.
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Mouse epidermal growth factor (mEGF) was purchased
from Sigma, Poole, Dorset as electrophoretically pure and
was iodinated without further processing. The iodination was
carried out by the lodogen method as described by Fraker &
Speck (1978) and Maddy et al. (1987). The final specific
activity of '25I-EGF vanred between 30 and 70pCipg .
Other chemicals
The following buffers were prepared and used throughout
the investigation: 1. Buffer A containing tris (10mmoll-'),
EDTA (Immoll-), EGTA (Immoll-), sucrose
(0.25molI1 ) and phenylmethylsulphonyl fluoride
(0.25mmolI -1); pH 7.4. 2. Buffer B containing tris
(lOmmoll-1), sodium chlonrde (0.9%), BSA (0.1%); pH 7.4.
3. 20% polyethylene glycol (PEG 8000MW, Sigma). Solu-
tion was prepared using buffer B. 4. 10% PEG solution was
prepared by diluting 20% PEG solution 1:2 using tris
1Ommol- 1) containing (0.9%) sodium chloride; pH 7.4.
Prostate tissue
Prostatic tissues were removed by transurethral resection
from 18 patients between 62 and 85 years of age with BPH
and 19 patients between 57 and 81 years with CaP. Large
uncharred resection chippings were selected for our bio-
chemical studies, placed in ice saline, blotted dry and
weighed. Several sections from each specimen were sent for
histological examination and grading of the cancerous tissue
by the Gleason system (Gleason, 1977). This system is based
upon the degree of glandular differentiation and the growth
pattern of the tumour in relation to the prostatic stroma.
The Gleason grade consists of two numbers, each between 1
and 5, which designate the primary and secondary pattern
according to the amount of each present in the specimen.
The sum of the two numbers is called the Gleason score and
it may range from 2 to 10. The remainder of the tissue was
either used fresh or snap frozen in liquid nitrogen and stored
at -70-C until analysis. None of the cancer patients had
received any therapy - endocrine or otherwise - before entry
into this study.
Tissue preparation
The following procedures were carried out at 4-C according
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to the method described by Maddy et al. (1987). About 1-2g
tissue was washed in buffer A, blotted dry and cut into small
pieces. Preliminary dispersion of the tissue was carried out
on a microdismembrator (B. Braun, AG Melsungen, FRG)
for 20s in a prechilled Teflon container. The tissue was
further homogenised in three volumes of buffer A using an
Ystral homogeniser (Scottish Scientific Instruments Centre
Ltd. Edinburgh) for two periods of 20s and 15s at position
6 with 1 min cooling intervals. The homogenate was subse-
quently filtered through a metal strainer and the filtrate spun
for 40min at 105,000g. The resultant pellet (total particulate
fraction) was resuspended in buffer B and dispersed further
in a glass Dounce homogeniser using 50 strokes with the
loose fitting pestle followed by 10 strokes with the tight
fitting pestle. The final concentration of the final particulate
fraction was adjusted to 1 mgml and this was used in
subsequent studies except where indicated otherwise.
Binding studies
Binding of EGF was determined by a modification of the
methods of Edery et al. (1985) and Maddy et al. (1987).
Briefly, homogenate samples were incubated with
8.0nmol 1 1 (200,000c.p.m. 125I-labelled EGF, specific
activity 30-70pCipg 1 in the presence and absence of 25-
fold excess (200 nmol 1 1) unlabelled EGF. The final volume
of the incubation mixture was 400pl made up of 200p1
buffer B with or without unlabelled EGF, 100p1 1251_
labelled EGF and I00pl sample. Incubation took place at
37-C for 90mmn and the reaction was terminated by the
addition of 1 ml of buffer B. Thereafter the bound complex
was separated from the free by PEG precipitation (Hwang et
al., 1986). The specific binding was calculated by subtracting
the non-specific from the total binding. Validation of the
assay for time and temperature of incubation, protein con-
centration and optimal pH range has already been estab-
lished and described in detail (Maddy et al., 1987). In our
hands, the sensitivity of the EGF-R assay was 1 fmolmg'
membrane protein.
Saturation analysis was performed over a range of 0.5-
12nmol 1251-labelled EGF-R in the presence and absence of
a 50-fold excess of unlabelled EGF at each concentration of
'251-labelled EGF. The dissociation constant (Kd) and bind-
ing sites were estimated by the Scatchard (1949) method.
Competition studies
Specificity of binding in CaP was assessed by incubating the
particulate fraction for 90min at 37-C with '251-labelled
EGF (8nmoll-1) in the absence and presence of the follow-
ing unlabelled competitors: venon nerve growth factor
(vNGF), hLH, hFSH, human-insulin, hGH, human-prolactin
and mEGF, all at concentrations ranging from 0 to
3000rngm-1-1, and specific binding was calculated.
Protein determination
Protein was estimated by the method of Bradford (1976)
using bovine serum albumin as standard.
Data analvsis
All incubations were performed in triplicate and the results
are presented as means +s.d. Differences in EGF-R between
the unpaired groups were tested for statistical significance by
Student's t test. Differences were considered statistically
significant when P was less than 0.05.
Results
The concentrations of EGF-R in 18 BPH and 19CaP have
been measured. The hyperplastic tissue exhibited an average
of 125 +7fmol of 1251-EGF per mg protein (Figure 1). In

















Fgre 1 Companrson of EGF-R in BPH (n= 18) and CaP
(n = 19). The 105,000g particulate fractions prepared from hyper-
plastic and malignant prostates were adjusted to 1 mg protein
ml -. The preparations were subsequently assayed for 1251 EGF
binding as described in the text and the specimens were grouped
according to their histological state. Each bar represents the
mean value for the EGF-R of all specimens within the
group±s.d. *Significantly different from other group (P<0.01).
bound by CaP. In spite of an overlap between the two
groups there was a statistically significant difference between
the levels of EGF-R in BPH and CaP (P<0.01). Although
all benign prostates assayed for EGF-R were found to be
positive, this was not the case in tumour specimens where
nine out of 19 were devoid of EGF binding or at least below
the detection limits of the assay.
In an attempt to ascertain whether the reduced binding in
cancer of the prostate was in any way associated with a
reduced affinity by the receptors for their ligand, experi-
ments were undertaken to establish the affinity and specifi-
city of the receptors for EGF. Analysis of the data from
saturation assays by the Scatchard method on four modera-
tely to well differentiated tumours revealed a linear plot
showing only one class of high affinity binding sites
(Kd= 1.6+0.4nmol 1) A typical saturation curve and Scat-
chard plot for the specific binding to the particulate fraction
is shown in Figure 2.
The specificity of the binding was also examined employ-
ing vNGF, hLH, hFSH, human-insulin, hGH, human-
prolactin and mnEGF at 500, 750, 1,000, 1,500 and
3,000ngml-1 as competitors. The data shown in Figure 3
reveal that the unlabelled mEGF competed in a dose related
manner with 124I-labelled mEGF for the binding sites wher-
eas the other ligands investigated did not displace the
labelled ligand from its binding sites.
Because of the significant difference between the mean
EGF-R values for the BPH and CaP groups, we decided to
analyse the receptor results of the cancerous specimens in
more detail. Tumours were classified according to their histo-
logical grade (Gleason score: primary+secondary pattern)
and these were in turn correlated to their various receptor
levels. The results illustrated in Figure 4 suggest a significant
correlation between the Gleason score and receptor concen-
trations: high receptor levels (mean=84+ 13 fmol mg pro-
tein -1) were always associated with good tumour
differentiation (Gleason score 2-4) whereas poorly differen-
tiated cancers (Gleason score 8-10) manifested a marked
-
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Figwe 2 Saturation curve and Scatchard plot of specific '25I-EGF binding to human prostate cancer. Aliquots (1001l) of the
membrane extraction were incubated with '251-labelled EGF (0.5-12nmoll-') in the presence and absence of 50-fold excess
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Figwe 3 Specifidty of the EGF binding sites in prostate cancer.
One hundred microlitre a}iquots of the membrane preparation
were incubated with '25I-labeled mouse EGF (8ni) at 3TC for
90mm in the absence and prsence of the competitor at the
concentrations indicated above. One hundred per cent compe-
tition was taken as the amount of 25I-labelled EGF dislac
by l,000ng unlabeld EGF per ml. Each value repesents the
mean+s.d. of three different sp each analysed in trip-
cate. x, VNGF; *, h-LH; L, h-FSH; A, h-ni; 0, h-GH
A, h-prolactin; 0, m-EGF.
suppression in their capacity to express the receptors
(22+5 fmol mg protein-1). On the other hand moderately
well differentiated tumours (Gleason score 5-7) demon-
strated receptor concentrations (53+8ffmolmgprotein-1)
which were significantly lower than those measured in the
well differentiated tumours but higher than the receptors
associated with poorly differentiated CaP. The differences


























Fige 4 Effect of tumour differentiation on the expression of
EGF receptors in cancer of the prostate. Following the measure-
ment of the EGF receptors as described in the Materials and
methods section, specamens were grouped according to the degree
of differentiation using the Gleason grading system (2-4, n=4;
5-7, n= 10; 8-10, n=5). Each bar represents the mean values for
the EGF receptors of all specimens within the same Gleason
score (primary+secondary pattern) and the results are expressed
as the mean+sd. Statistical analyss of signifi between the
different groups were made by Student's t test. *Significanly
diffemnt from all other groups (P<0.01).
Although other reports have established the presence of
EGF-R in human BPH (Maddy et al., 1987; Eaton et al.,
1988), this is the first time that a significant correlation has
been demonstrated between the expression of EGF-R and
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the present study 19 prostatic cancers of varying degrees of
differentiation were examined for their EGF-R concent-
rations and these measurements were in turn compared with
those obtained in benign prostatic hyperplasia from an aged
matched group. Our data indicated significant differences in
EGF-R concentrations for both tissue types with the mean
value of the cancer tissue being markedly depleted when
compared to the hyperplastic specimens (P<0.01). Further-
more, grouping of the tumours according to their histologi-
cal grade indicated that there was a diminished propensity to
express EGF-R as tumours progressively became less differ-
entiated; in this respect EGF-R could be used as further
confirmatory evidence for the histopathological grading of
CaP. In the present study we chose the Gleason grading
system (Gleason, 1977) as an index of the degree of differen-
tiation because it provides a more detailed insight into the
nature of any particular tumour than the simple three grade
system (Beynon et al., 1983).
These findings are supported by other workers who also
demonstrated that the receptor expressions with a variety of
other tissues in the cancer state were inversely proportional
to the metastatic potential of the tumour. Thus increased
levels of EGF-R expression were associated with well
differentiated tumours whereas poorly differentiated cancers
correlated with a reduced receptor expression (Gusterson et
al., 1984; Gullick et al., 1986). However, these trends are not
universal, as shown by the recent studies on breast cancer
(Sainsbury et al., 1985). invasive and superficial bladder
cancer (Neal et al., 1985) and squamous carcinoma cells
(Ozanne et al., 1985; Cowley et al., 1986) where EGF-R
expression was significantly amplified as the tumours pro-
gressed to the metastatic state. Of interest too are the
dissociation constant values for CaP which are of the same
order of magnitude as those previously measured in BPH
(Maddy et al., 1987). Our results demonstrate that the
reduced binding capacity of CaP is not induced by changes
in the affinity of the receptor for its ligand; such changes are
not uncommon and have been reported in earlier studies on
human oesophagus carcinoma cells (Banks-Schlegel &
Quintero, 1986).
The mechanisms by which EGF-Rs are implicated in the
malignant transformation are not well defined but one
possibility for the increase in receptor levels stems from an
amplification and rearrangement of the receptor gene
(Bradley et al., 1986). Loss of receptors, on the other hand,
has been attributed to several factors, of which internalisa-
tion (Kay et al., 1986), expression of truncated EGF recep-
tors (Ozanne et al., 1984) and total absence of EGF-R gene
expression (Robinson et al., 1982) are the most likely to be
involved. We are at present considering all these possibilities
with a view to identifying the causes responsible for EGF-R
depletion in cancer of the prostate.
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